Ameriprise’s Ascendis Pharma A/S ASND Stock Holding History

Ameriprise’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$109M	Sell	476,466 -74,011	-13%	-$16.6M	0.03%	527
2025 Q4	$117M	Sell	550,477 -12,459	-2%	-$2.57M	0.03%	506
2025 Q3	$112M	Sell	562,936 -25,133	-4%	-$4.69M	0.03%	525
2025 Q2	$102M	Sell	588,069 -91,874	-14%	-$15M	0.03%	546
2025 Q1	$106M	Sell	679,943 -22,618	-3%	-$3.23M	0.03%	517
2024 Q4	$96.7M	Buy	702,561 +32,844	+5%	+$4.32M	0.02%	560
2024 Q3	$100M	Buy	669,717 +9,055	+1%	+$1.22M	0.03%	548
2024 Q2	$90.1M	Buy	660,662 +605,496	+1,098%	+$82.4M	0.02%	559
2024 Q1	$8.34M	Sell	55,166 -7,144	-11%	-$1.02M	﹤0.01%	1952
2023 Q4	$7.85M	Buy	62,310 +1,734	+3%	+$173K	﹤0.01%	1993
2023 Q3	$5.67M	Sell	60,576 -8,043	-12%	-$752K	﹤0.01%	2183
2023 Q2	$6.12M	Buy	68,619 +14,586	+27%	+$1.27M	﹤0.01%	2183
2023 Q1	$5.79M	Sell	54,033 -103	-0.2%	-$11.8K	﹤0.01%	2214
2022 Q4	$6.61M	Sell	54,136 -331	-0.6%	-$38.4K	﹤0.01%	2088
2022 Q3	$5.63M	Buy	54,467 +4,302	+9%	+$408K	﹤0.01%	2126
2022 Q2	$4.66M	Sell	50,165 -1,644	-3%	-$155K	﹤0.01%	2334
2022 Q1	$6.08M	Buy	51,809 +3,232	+7%	+$374K	﹤0.01%	2293
2021 Q4	$6.54M	Sell	48,577 -2,610	-5%	-$388K	﹤0.01%	2281
2021 Q3	$8.16M	Sell	51,187 -1,344	-3%	-$184K	﹤0.01%	2026
2021 Q2	$6.91M	Buy	52,531 +4,494	+9%	+$599K	﹤0.01%	2221
2021 Q1	$6.19M	Sell	48,037 -22,119	-32%	-$3.36M	﹤0.01%	2259
2020 Q4	$11.7M	Sell	70,156 -2,674	-4%	-$442K	﹤0.01%	1631
2020 Q3	$11.2M	Sell	72,830 -933	-1%	-$134K	﹤0.01%	1476
2020 Q2	$10.9M	Buy	73,763 +61	+0.1%	+$8.38K	﹤0.01%	1477
2020 Q1	$8.3M	Sell	73,702 -24,731	-25%	-$3.21M	﹤0.01%	1531
2019 Q4	$13.7M	Buy	98,433 +240	+0.2%	+$26.7K	0.01%	1488
2019 Q3	$9.46M	Sell	98,193 -7,838	-7%	-$874K	﹤0.01%	1737
2019 Q2	$12.2M	Buy	106,031 +42,448	+67%	+$5.08M	0.01%	1570
2019 Q1	$7.48M	Buy	+63,583	New	+$5.57M	﹤0.01%	1935

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameriprise's ASND Position: Q1 2026 in Review

Ameriprise reduced its Ascendis Pharma A/S (ASND) stake by 13% in Q1 2026, selling an estimated $16.6M and leaving 476,466 shares worth $109M. The position accounts for 0.03% of the portfolio, ranked #527.

Ameriprise first reported a position in ASND in Q1 2019 and has held it in 29 quarters since. The position peaked at $117M in Q4 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Ameriprise held 476,466 shares of Ascendis Pharma A/S worth $109M as of Q1 2026.
Ameriprise sold 74,011 Ascendis Pharma A/S shares in Q1 2026, an estimated $16.6M.
Ascendis Pharma A/S made up 0.03% of Ameriprise's portfolio in Q1 2026, its #527 holding.
Ameriprise first reported a position in Ascendis Pharma A/S in Q1 2019 and has held it in 29 quarters since.
Ameriprise's Ascendis Pharma A/S position peaked at $117M in Q4 2025.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.